-

Hims & Hers Data Shows Personalized GLP-1 Plans Drive Real Weight Loss, Few Side Effects, and Strong Adherence to Care

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today released new data showing that its personalized, digital-first approach to weight loss is driving meaningful, sustainable results, laying the groundwork for lasting success. In a first-of-its-kind U.S. analysis of treatment plans, including compounded GLP-1s, customers taking a compounded GLP-1 reported losing an average of 20.9 pounds or 10.3% of initial body weight, within six months, while reporting a low rate of side effects. Just as importantly, 75% of customers remained on treatment plans in the same timeframe, a powerful signal of real-world trust and clinical success.1

Unlike traditional care models that often leave patients to navigate treatment alone, Hims & Hers delivers access to a holistic weight loss program that combines personalized dosing when clinically necessary, 24/7 care team access, and educational support across nutrition, mental health, and physical wellness. The result: a scalable, high-quality model that empowers individuals, builds long-term trust, and helps people succeed.

Key findings from the new analysis indicate:

  • Holistic model helps people stick with their treatment: While dropout rates for commercially available GLP-1s can hover around 80% at six months2, only 25% of Hims & Hers customers discontinued treatment in that timeframe, highlighting the strength and confidence a holistic, personalized model delivers. While these results cannot be directly compared, it is encouraging that Hims & Hers customers appear to stick to their treatment plans in high numbers.
  • Personalized treatment plans drive significant weight loss, with low rates of side effects and high safety: Customers lost an average of 20.9 pounds, or 10.3% of their initial body weight in six months. Among these same customers, only 10.3% reported side effects, and an even smaller 4.5% reported intolerable side effects. Among those who completed a 6-month check-in, 97% of customers on plans with compounded GLP-1s reported an improvement in their overall health.
  • Always-on support empowers customers beyond the prescription: The platform combines 24/7 care team access with curated education across nutrition, mental health, and physical wellness. Customers exchanged over 6.7 million messages with their care teams, with 75% receiving responses in 5 hours or less3. In fact, the majority of customers (73%) preferred their digital health experience with Hims & Hers over other programs or providers4.
  • Care in hours, not months, designed to scale without compromise: The average wait time to see an obesity medicine specialist in the U.S. is approximately 5 months5. In contrast, the average wait time for a Hims & Hers Weight Loss customer to have their online medical intake evaluated by a licensed provider is approximately 3 hours.6

"My two decades as an obesity medicine specialist have shown me that lasting weight loss hinges on treating the individual, not just the condition. The true power of Hims & Hers lies in our ability to deliver access to truly bespoke care: from personalized dosing and tailored nutritional guidance to 24/7 access to reach out to their care team,” said Craig Primack MD, Head of Weight Loss, Hims & Hers. “Medication is a powerful component, but it's just one part of the comprehensive support system people need for this transformative health journey. Today's findings strongly signal that a digital-first, personalized experience is precisely what helps people stick to their treatment plans to drive lasting outcomes."

Download the full white paper here.

About Hims & Hers Health, Inc.

Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalized care designed for results. For more information, please visit www.hims.com and www.forhers.com.

____________________

1

Hims & Hers evaluated de-identified data from 13,458 Weight Loss customers prescribed a compounded injectable GLP-1 medication through our platform who completed a 6-month check. — Hims & Hers, The 1-Year Journey of Hims & Hers Weight Loss Customers, White Paper, 2025.

2

Blue Health Intelligence. (2024). Real-world trends in GLP-1 treatment persistence and prescribing for weight management. https://www.bcbs.com/media/pdf/BHI_Issue_Brief_GLP1_Trends.pdf

3

Hims & Hers Internal Data, as of June 30, 2025

4

Hims & Hers Customer Insights and User Experience Weight Loss Survey, July 2025

5

Rustagi, R. (2023). Regional disparities in access to obesity care: Analysis of wait times in top U.S. hospitals [conference presentation]. World Obesity and Weight Management Congress 2023. Boston, MA. https://obesityworldconference.com/program/scientific-program/2023/regional-disparities-in-access-to-obesity-care-an-analysis-of-wait-times-in-top-u-s-hospitals

6

Hims & Hers Internal Data, as of June 30, 2025

 

Contacts

Press Contact
Susan Cadrecha
press@forhims.com

Hims & Hers

NYSE:HIMS

Release Versions

Contacts

Press Contact
Susan Cadrecha
press@forhims.com
More News From Hims & Hers

Hims & Hers to Announce Second Quarter 2025 Financial Results on August 4, 2025

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced that it will report second quarter 2025 financial results after the market closes on Monday, August 4, 2025. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, refer...

Hims & Hers Announces Planned 2026 Expansion to Canada, Following ZAVA Acquisition Completion

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS) the leading digital health and wellness platform, today announced its plans to bring its affordable, holistic weight loss program to Canada, timed with the anticipated first-ever availability of generic semaglutide anywhere in the world. This move follows the recent closing of the company's acquisition of ZAVA, the pioneering digital health platform in Europe. Almost two thirds of adults in Canada are overweight or living...

Hims & Hers Announces Plans to Acquire ZAVA, Accelerating Major European Growth Across the UK, Germany, France, and Ireland

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced a significant step in its global expansion through its agreement to acquire ZAVA, a leading digital health platform in Europe. This strategic move will expand Hims & Hers' footprint in the United Kingdom and will officially launch the company into Germany, France, and Ireland, with more markets anticipated soon. This acquisition is expected to accelerate Hims...
Back to Newsroom